Profound Medical Corp. (PROF) stock intrinsic value fair value estimate & owner earnings analysis

Profound Medical sells two ultrasound ablation systems: TULSA-PRO, an MRI-guided, incision-free treatment for prostate tissue sold mainly in the United States, and Sonalleve, sold mainly outside North America. Revenue in 2025 was $16.1 million, up 51% from $10.7 million. Recurring revenue (single-use devices and service plans) was $9.7 million, up from $8.2 million, and capital equipment sales were $6.4 million, up from $2.4 million. Gross margin rose to 71% from 66%. The business does not yet earn money. Operating expenses were $52.6 million in 2025 (research and development $20.6 million, selling and administrative $32.1 million), up 31%, against gross profit of $11.4 million. The net loss was $42.6 million. Cash used by operations was $38.2 million, versus $23.5 million in 2024. Owner earnings, which we define as operating cash flow less working-capital swings, less stock compensation, less maintenance capital spending, were negative in every year we can measure: about -$1.27 per share in 2023, -$1.07 in 2024 and -$1.39 in 2025. Stock compensation is a real cost and was $5.5 million in 2025, more than double 2024. Capital spending is tiny ($0.2 million in 2025), so almost all of the loss is operating. Revenue more than doubled between 2023 ($7.2 million) and 2025 ($16.1 million), yet the net loss grew from $28.3 million to $42.6 million. Growth so far has not narrowed the loss. We test the argument for profitability with one fact. At the 2025 gross margin of about 71%, revenue would need to be roughly $74 million just to cover 2025 operating expenses, over four and a half times what the company sold. The filing says expenses are expected to keep rising as TULSA-PRO and Sonalleve are commercialized. Nothing in the filings commits the company to lower spending or shows a date when revenue reaches that level, so we do not credit it. Base case: the company keeps spending at or above the current level. We assign no earnings value because we can name no contracted or proven mechanism that turns the current loss into a profit. Growth in recurring revenue is real but is not enough, and it is not in the bag for this purpose. Value is $0 per share. Bear case: the cash burn continues and the company must keep selling new shares. It sold 6,064,298 shares at $7.00 in December 2025, raising $40.8 million net, and that money is being spent. Cash was $59.7 million at year-end 2025 and $38.3 million at June 30, 2026, after $19.9 million of operating cash use in the first half. The bank line (a $10 million revolver from CIBC maturing March 3, 2027) requires cash of at least $10 million or the last six months' loss if larger, so lenders are also a constraint. Existing holders end up worth $0. Bull case: management stops the burn while cash remains. That is within its control, since spending is discretionary, but nothing in the filings says it will happen, so we value only what is on hand: about $1.05 per share ($38.3 million of cash at June 30, 2026 over about 36.35 million shares). This is a floor-style value, not an earnings value, and it falls each quarter the burn continues. The 10-K says existing cash and sales should fund operating expenses for at least 12 months from the filing date, and it carries no going-concern warning. It does say that failure to raise enough additional capital could create substantial doubt. The TACT and CAPTAIN prostate trials are worth watching. CAPTAIN finished enrolling 211 patients in 2025 and compares TULSA to surgery for intermediate-risk prostate cancer. Favorable data could speed adoption, but adoption speed is not a driver we can evidence today. What would make this wrong: revenue compounding fast enough, with operating expenses held flat, to reach roughly $74 million of sales, or a decision to cut spending sharply while keeping growth. Either would show up first as smaller operating cash burn. We also could not verify quarterly detail beyond the June 2026 cash balance and first-half figures. Full-year 2023 owner earnings use the FY2024 annual report; earlier years were not available in our data.